Enoblituzumab

依布妥组单抗

Report date: 2026/03/27 20:01:50

Base Information

Drug NameEnoblituzumab
Drug Alias NameMGA-271TJ271
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of MinnesotaMacrogenics IncI-Mab Biopharma Co Ltd
Inactive CompaniesI-Mab Biopharma Us Ltd
Active IndicationsProstatic NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsTriple Negative Breast Neoplasms +[13] 

Other Information

ATC CodeN/A
Related LinksWikipedia